Business context and reporting period
Entity discrepancy: The request identifies Larimar Therapeutics, Inc., but the supplied Form 10-Q is for Zafgen, Inc. It covers the quarter ended June 30, 2014, and was signed August 14, 2014. The summary below reflects the filing, not Larimar.
Zafgen was a clinical-stage biopharmaceutical company with no product revenue. Its lead candidate, beloranib, was being developed for Prader-Willi syndrome (PWS), hypothalamic injury-associated obesity and severe obesity; ZGN-839 and other MetAP2 inhibitors were earlier-stage programs.
Financial performance and position
Unless noted otherwise, amounts are in millions of U.S. dollars. The filing presents financial results in thousands.
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $4.695 | $1.961 | $7.970 | $4.594 |
| General and administrative expense | $1.291 | $1.014 | $2.537 | $1.901 |
| Total operating expenses | $5.986 | $2.975 | $10.507 | $6.495 |
| Net loss | $(6.400) | $(3.136) | $(10.858) | $(6.677) |
| Net loss attributable to common stockholders | $(6.443) | $(3.190) | $(10.950) | $(6.784) |
No meaningful revenue margin was reported because the company had no revenue. Net loss per share attributable to common stockholders was $(2.96) for Q2 2014 and $(7.51) for the first half of 2014; comparative 2013 figures were $(4.37) and $(9.31), respectively.
- Cash and liquidity: Cash and cash equivalents were $134.233 million at June 30, 2014, versus $35.517 million at December 31, 2013. Current assets were $136.822 million and current liabilities were $4.102 million.
- Cash flow: First-half operating cash use was $10.249 million, investing cash use was $0.068 million, and financing provided $109.033 million. Cash increased $98.716 million over the period.
- Debt: Long-term notes payable, net of discount, were $7.447 million. The March 2014 credit facility authorized up to $20 million; Zafgen drew $7.5 million initially, did not take the conditional $5 million post-IPO tranche, and had a further $7.5 million tranche available through September 30, 2014. Borrowings bore 8.1% annual interest and were secured by substantially all personal property except intellectual property.
- Equity financing: The June IPO sold 6.9 million shares at $16 per share, generating approximately $102.7 million in net proceeds after underwriting discounts and commissions. The company also reported approximately $2.5 million of other offering costs.
- Balance sheet: Total assets were $136.968 million and total liabilities were $11.549 million at June 30, 2014. Accumulated deficit was $79.765 million.
Changes versus the prior comparable period
- Q2 operating expenses rose $3.011 million year over year, driven primarily by a $2.734 million increase in R&D. First-half operating expenses increased $4.012 million year over year.
- Beloranib R&D spending increased, particularly for preclinical work and manufacturing to prepare for later trials. First-half clinical-trial expense for beloranib declined year over year, partly because the 2013 severe-obesity Phase 2a trial had concluded.
- First-half net loss increased $4.181 million year over year, including $0.445 million of interest expense associated with the new credit facility. The company had no debt outstanding at December 31, 2013.
- Cash rose substantially following the IPO. All outstanding redeemable convertible preferred stock converted to common stock at the IPO closing.
Outlook, commentary, risks and unusual items
- Management stated that existing cash and available credit were expected to fund operating expenses and capital requirements for at least the next 12 months, while cautioning that assumptions could prove wrong and capital could be used sooner than expected.
- Management expected expenses and operating losses to increase as it advanced beloranib into later-stage trials, developed earlier-stage candidates, expanded operations and incurred public-company costs. No quantified earnings or revenue guidance was provided.
- The company planned to begin its PWS Phase 3 program and a severe-obesity Phase 2b trial in the second half of 2014; the latter was subject to planned FDA discussions. A Phase 2a trial for hypothalamic injury-associated obesity had begun in June 2014. Timing depended on regulatory feedback, trial design, enrollment and drug supply.
- Clinical risk was significant: beloranib remained in development, positive early-stage results might not be replicated, and the filing cited sleep disturbances, nausea and vomiting as main adverse events in completed Phase 2a trials. Zafgen reported no serious adverse events attributed to beloranib in its trials to date.
- Manufacturing was a near-term execution risk. Finished drug product, diluent and placebo were expected in Q3 2014; delays could postpone additional trials. The company relied on a small number of third-party manufacturers and clinical research organizations.
- Beloranib license agreements included contingent milestones of up to $18.95 million for pre-commercialization milestones and $12.5 million for commercialization milestones, plus up to $1.25 million for each qualifying subsequent licensed product under one agreement. The company anticipated up to $6.7 million of 2014 milestone payments if development milestones were achieved; these contingent amounts were not recorded as liabilities.
- Other risks included reliance on beloranib, uncertain regulatory approval and market adoption, future financing needs, intellectual-property protection, foreign-currency exposure and competition. A 10% unfavorable currency movement was estimated to increase first-half net loss by $0.2 million. No legal proceedings were reported as of the filing date.
- Management said disclosure controls were effective at the reasonable-assurance level and reported no material changes in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm whether the intended filing is Zafgen’s 2014 Q2 10-Q or a Larimar Therapeutics filing; the supplied document names Zafgen.
- Verify clinical-trial start dates, regulatory feedback, required trial scope and beloranib safety updates against subsequent disclosures.
- Check whether the expected Q3 2014 drug-supply milestones were met and whether supply supported planned trials.
- Assess cash burn and runway against the stated 12-month estimate, including any additional credit-facility draw and contingent milestone payments.
- Reconcile the filing’s preferred-stock conversion share counts: one passage reports 15,077,621 shares, while another reports 15,132,026 shares.